JNJ-55308942 clinical trials
Also written JNJ-55308942.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How each study uses JNJ-55308942 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- JNJ-55308942
- 2
Studies by the year they started
4 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Janssen-Cilag International NV (3) · Janssen Pharmaceutica N.V., Belgium (1)
Often tested with
Tested in the same studies.
Levonorgestrel (1) · Ethinyl Estradiol (1) · JNJ-64413739 (1)
Studies
Open first, then newest update. How each study uses JNJ-55308942 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study of JNJ-55308942 in the Treatment of Bipolar DepressionCompletedPhase 2Janssen Pharmaceutica N.V., BelgiumNCT05328297Written as JNJ-55308942
- A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-55308942 in Healthy Male and Female ParticipantsCompletedPhase 1Janssen-Cilag International NVNCT03151486Written as JNJ-55308942 0.5 mg
- A Study in Healthy Participants to Evaluate the Effects of Multiple Doses of JNJ-55308942 on Cytochrome P450 Substrate Activity and on the Pharmacokinetics of Levonorgestrel/Ethinyl EstradiolCompletedPhase 1Janssen-Cilag International NVNCT03547024Written as JNJ-55308942 High Dose
- A Positron Emission Tomography (PET) Study to Investigate P2X7 Receptor Occupancy by JNJ-55308942 Using [18F]-JNJ-64413739CompletedPhase 1Janssen-Cilag International NVNCT03437590Written as JNJ-55308942
Codes
What other systems call JNJ-55308942 · ClinicalTrials.gg INT001066
- MeSH (NLM) C000630474JNJ-55308942One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000630474 | JNJ-55308942 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.